Drug intelligence / Profile preview

XPACE-1001

Development stage: Preclinical
Lead developer: Xanadu Bio
Modality: Vaccines & Immunotherapeutics

Overview

XPACE-1001 is a preclinical-stage therapeutic candidate developed by Xanadu Bio targeting **CFTR** (cystic fibrosis transmembrane conductance regulator) for the treatment of **cystic fibrosis**. It functions as a **CFTR modulator**, a class of agents designed to correct the defective CFTR protein underlying the disease, potentially restoring chloride ion transport across epithelial cell membranes to alleviate mucus buildup in the lungs and other organs. Xanadu Bio's pipeline emphasizes mRNA-based technologies, though specific details on XPACE-1001's formulation remain undisclosed.[1]

Targets

CFTR (Cystic fibrosis transmembrane conductance regulator)

Beyond the preview

Go deeper on XPACE-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XPACE-1001.

Explore the full profile